Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib

Jacobs, Jeffrey; Clark‐Snustad, Kindra; Lee, Scott

doi:10.1093/ibd/izaa093

Cited by 36 publications

(41 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IL-6 targets the IL-6 receptor, and the letter recruit JAK, which transit cascade signal to activate signal transducer and activator of transcription 3 (STAT3) ( 119 ). Some physicians suggest tofacitinib, a small molecule compound target JAK1 and JAK3, could be applied in the treatment of COVID-19, and tofacitinib success in treating a COVID-19 patient complicated with ulcerative colitis ( 134 ). IL-10, a cytokine with anti-inflammatory properties, could be secreted by virtually all immune cells, including macrophages, DCs, NK cells, T cells, and B cells ( 135 ).…”

Section: Discussionmentioning

confidence: 99%

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

et al. 2020

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is the pathogen that causes coronavirus disease 2019 (COVID-19). As of 25 May 2020, the outbreak of COVID-19 has caused 347,192 deaths around the world. The current evidence showed that severely ill patients tend to have a high concentration of pro-inflammatory cytokines, such as interleukin (IL)-6, compared to those who are moderately ill. The high level of cytokines also indicates a poor prognosis in COVID-19. Besides, excessive infiltration of pro-inflammatory cells, mainly involving macrophages and T-helper 17 cells, has been found in lung tissues of patients with COVID-19 by postmortem examination. Recently, increasing studies indicate that the “cytokine storm” may contribute to the mortality of COVID-19. Here, we summarize the clinical and pathologic features of the cytokine storm in COVID-19. Our review shows that SARS-Cov-2 selectively induces a high level of IL-6 and results in the exhaustion of lymphocytes. The current evidence indicates that tocilizumab, an IL-6 inhibitor, is relatively effective and safe. Besides, corticosteroids, programmed cell death protein (PD)-1/PD-L1 checkpoint inhibition, cytokine-adsorption devices, intravenous immunoglobulin, and antimalarial agents could be potentially useful and reliable approaches to counteract cytokine storm in COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Among the 87 records that were identified through electronic search after duplicates removal, both reviewers independently evaluated the titles and abstracts, removed 68 studies that did not meet the inclusion criteria, and selected 19 potentially relevant reports that were identified and retrieved for detailed evaluation. Among these, 18 papers [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] were included in the qualitative synthesis ( Fig. 1 ).…”

Section: Methodsmentioning

confidence: 99%

COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data

Macaluso

Orlando

2020

Digestive and Liver Disease

View full text Add to dashboard Cite

Background Great efforts by the scientific community are rapidly expanding the evidence on the clinical interplay between Covid-19 and inflammatory bowel disease (IBD). Aims We performed a systematic review of the literature on published Covid-19 cases occurring in patients with IBD. Methods PubMed Central/Medline and Embase were systemically searched for records up to May 31, 2020. Results 13 cohort studies and 5 single case reports were included in the qualitative synthesis. A cumulative number of approximately 800 patients with IBD and Covid-19 were identified. The case fatality rate ranged from 0% to 20.0%. Overall, immunomodulators and biologics were not associated with higher risk of Covid-19 or with negative outcomes, while the use of systemic corticosteroids was related to worse prognosis in some studies. Conclusions This systematic review highlighted two main points that may help clinicians dealing with IBD in reassuring their patients: (1) patients with IBD do not seem to be at higher risk of being infected by SARS-COV-2 than the general population; (2) in case of Covid-19, treatment with immunomodulators or biologics is not associated with worse prognosis, while systemic steroids are suspected to be potentially detrimental, even if more data are needed to confirm this point.

show abstract

“…Preliminary studies did not report any COVID-19 cases in patients with IBD ( 1 , 2 ). However, subsequent studies including the Surveillance Epidemiology of Coronavirus Under Research Exclusion-IBD database, which includes global data of patients with IBD and COVID-19 ( 3 ), several cohort studies ( 4 – 9 ), and case reports ( 10 – 12 ), have reported 1,258 patients with IBD affected by COVID-19. Pooled data suggest that COVID-19 does not occur more frequently in patients with IBD than in the general population ( 6 – 8 ).…”

Section: Epidemiology Of Covid-19 In Ibdmentioning

confidence: 99%

Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease

2020

View full text Add to dashboard Cite

INTRODUCTION: It has been hypothesized that people suffering from inflammatory bowel disease (IBD) have an increased risk of coronavirus disease (COVID-19). However, it is not known whether immunosuppressive therapies exacerbate the COVID-19 outcome. METHODS: We reviewed data on the prevalence and clinical outcomes of COVID-19 in patients with IBD. RESULTS: COVID-19 prevalence in patients with IBD was comparable with that in the general population. Therapies using antitumor necrosis factor-α agents have been associated with better clinical outcomes. DISCUSSION: Management and treatments provided by gastroenterologists were effective in reducing COVID-19 risk. Antitumor necrosis factor-α agents seem to mitigate the course of COVID-19.

show abstract

Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib

Cited by 36 publications

References 4 publications

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data

Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease

Contact Info

Product

Resources

About